Plasma biomarkers identify brain ATN abnormalities in a dementia-free population-based cohort
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
INTRODUCTION
Using the ATN framework, we evaluated the potential of plasma biomarkers to identify abnormal brain amyloid-beta (Aβ) positron emission tomography (PET), tau-PET and neurodegeneration in a socioeconomically disadvantaged population-based cohort.
METHODS
Community-dwelling dementia-free (n=113, including 102 (91%) cognitively normal) participants underwent ATN neuroimaging and plasma biomarker assessments.
RESULTS
Plasma Aβ42/Aβ40, p-tau181, and p-tau217 showed significant associations with Aβ-PET status (adjusted odds ratio [AOR] of 1.74*10 -24 , 1.47, and 3.43*10 3 respectively [p- values<0.05]), with p-tau217 demonstrating the highest classification accuracy for Aβ-PET status (AUC=0.94). Plasma p-tau181 and p-tau217 showed significant associations with tau- PET status (AOR: 1.50 and 22.24, respectively, p-values<0.05), with comparable classification accuracies for tau-PET status (AUC=0.74 and 0.70, respectively). Only plasma NfL showed significant association with neurodegeneration based on cortical thickness (AOR=1.09, p- value<0.05).
CONCLUSION
Our findings highlight potential of plasma p-tau217 as a biomarker for brain Aβ and tau pathophysiology, p-tau181 for tau abnormalities, and NfL for neurodegeneration in the community.
